Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways

• Published in: Cell death & disease 2013-10, Vol.4 (10), p.e878-e878
• Main Authors: Bruzzese, F, Pucci, B, Milone, M R, Ciardiello, C, Franco, R, Chianese, M I, Rocco, M, Di Gennaro, E, Leone, A, Luciano, A, Arra, C, Santini, D, Caraglia, M, Budillon, A
• Format: Article
• Language: English
• Subjects: 631/67/1990/804; 631/67/589/466; 631/80/86; 692/700/565/1436/1437; Animals; Antibodies; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Apoptosis - drug effects; Biochemistry; Biomedical and Life Sciences; Cell Biology; Cell Culture; Diphosphonates - pharmacology; Diphosphonates - therapeutic use; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm - drug effects; Drug Synergism; Enzyme Activation - drug effects; Humans; Hydroxamic Acids - pharmacology; Hydroxamic Acids - therapeutic use; Imidazoles - pharmacology; Imidazoles - therapeutic use; Immunology; Indoles - pharmacology; Indoles - therapeutic use; Life Sciences; Male; Mevalonic Acid - metabolism; Mice; Mice, Nude; Models, Biological; Multiple Myeloma - drug therapy; Multiple Myeloma - enzymology; Multiple Myeloma - pathology; Original; original-article; p38 Mitogen-Activated Protein Kinases - metabolism; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - enzymology; Prostatic Neoplasms - pathology; Reactive Oxygen Species - metabolism; Signal Transduction - drug effects; Xenograft Model Antitumor Assays
• ISSN: 2041-4889; 2041-4889
• DOI: 10.1038/cddis.2013.406

Patients with advanced prostate cancer (PCa) and multiple myeloma (MM) have limited long-term responses to available therapies. The histone deacetylase inhibitor panobinostat has shown significant preclinical and clinical anticancer activity in both hematological and solid malignancies and is currently in phase III trials for relapsed MM. Bisphosphonates (BPs), such as zoledronic acid (ZOL), inhibit osteoclast-mediated bone resorption and are indicated for the treatment of bone metastasis. BPs, including ZOL, have also shown anticancer activity in several preclinical and clinical studies. In the present report, we found a potent synergistic antiproliferative effect of panobinostat/ZOL treatment in three PCa and three MM cell lines as well as in a PCa ZOL-resistant subline, independently of p53/KRAS status, androgen dependency, or the schedule of administration. The synergistic effect was also observed in an anchorage-independent agar assay in both ZOL-sensitive and ZOL-resistant cells and was confirmed in vivo in a PCa xenograft model. The co-administration of the antioxidant N -acetyl- L -cysteine blocked the increased reactive oxygen species generation and apoptosis observed in the combination setting compared with control or single-agent treatments, suggesting that oxidative injury plays a functional role in the synergism. Proapoptotic synergy was also partially antagonized by the addition of geranyl-geraniol, which bypasses the inhibition of farnesylpyrophosphate synthase by ZOL in the mevalonate pathway, supporting the involvement of this pathway in the synergy. Finally, at the molecular level, the inhibition of basal and ZOL-induced activation of p38-MAPK by panobinostat in sensitive and ZOL-resistant cells and in tumor xenografts could explain, at least in part, the observed synergism.